Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 33571036)

  • 1. Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China.
    Guan X; Li H; Xiong X; Peng C; Wang N; Ma X; Ma A
    J Med Econ; 2021; 24(1):339-344. PubMed ID: 33571036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China.
    Peng Z; Hou X; Huang Y; Xie T; Hua X
    BMC Cancer; 2020 Oct; 20(1):990. PubMed ID: 33050905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer.
    Zhang PF; Xie D; Li Q
    Tumori; 2020 Oct; 106(5):400-405. PubMed ID: 32354261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
    Zhang Q; Wang Q; Wang X; Li J; Shen L; Peng Z
    Int J Colorectal Dis; 2020 Feb; 35(2):295-306. PubMed ID: 31848739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.
    Goldstein DA; Ahmad BB; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
    J Clin Oncol; 2015 Nov; 33(32):3727-32. PubMed ID: 26304904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
    Parikh ND; Singal AG; Hutton DW
    Cancer; 2017 Oct; 123(19):3725-3731. PubMed ID: 28662266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis.
    Jing Z; Rui Z; Binglan Z
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2313-2323. PubMed ID: 31278474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan.
    Kashiwa M; Matsushita R
    Clin Ther; 2020 Jul; 42(7):1376-1387. PubMed ID: 32653227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
    Chen J; Wang J; Lin H; Peng Y
    Med Sci Monit; 2019 Dec; 25():9179-9191. PubMed ID: 31790382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China.
    Ma Y; Zhou J; Ye Y; Wang X; Ma A; Li H
    Front Oncol; 2023; 13():1113346. PubMed ID: 37182176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.
    Cho SK; Hay JW; Barzi A
    Clin Colorectal Cancer; 2018 Dec; 17(4):e751-e761. PubMed ID: 30228027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.
    Shlomai A; Leshno M; Goldstein DA
    PLoS One; 2018; 13(11):e0207132. PubMed ID: 30408106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
    Bullement A; Underhill S; Fougeray R; Hatswell AJ
    Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of fruquintinib in Chinese patients with refractory metastatic colorectal cancer.
    Huang Z; Zhou L; Zheng H; Zhan M
    Int J Clin Pharm; 2024 Apr; ():. PubMed ID: 38642249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
    Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
    Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial.
    Qin S; Li J; Bai Y; Deng Y; Yang L; Xu RH; Zhong H; Chen Z; Pan H; Guo W; Shu Y; Xu J; Peng C; Chen Y; Li H; Wang N; Guo X; Peng M; Fan S; Shen L
    Future Oncol; 2021 May; 17(15):1923-1931. PubMed ID: 33563040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China.
    Wu Q; Zhang P; Wang X; Zhang M; Liao W; Li Q
    Clin Ther; 2020 Nov; 42(11):2148-2158.e2. PubMed ID: 32981743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third-line treatment for metastatic colorectal cancer: anlotinib is superior to chemotherapy and similar to fruquintinib or regorafenib.
    Cheng Y; Du FC; Fang FQ; Duan ZJ; Lei W; Shi KG
    Neoplasma; 2020 Nov; 67(6):1384-1390. PubMed ID: 32657613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
    Zhang Q; Chen M; Wang Z; Qi C; Cao Y; Zhang J; Peng Z; Wang X; Lu M; Shen L; Li J
    Clin Colorectal Cancer; 2022 Sep; 21(3):e152-e161. PubMed ID: 35216918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.